Talk:Binimetinib

Latest comment: 8 years ago by Rod57 in topic NDA submitted June 2016


NDA submitted June 2016

edit

Array Bio submits marketing application in U.S. for lead product candidate in certain type of melanoma says "Array BioPharma files a New Drug Application (NDA) with the FDA seeking approval of ... binimetinib for the treatment [of] NRAS mutation-positive melanoma. [based on] the Phase 3 NEMO study which showed an improvement in progression-free survival versus the chemo agent dacarbazine." - Rod57 (talk) 11:03, 5 July 2016 (UTC)Reply